First Manhattan’s Trinity Biotech TRIB Stock Holding History

First Manhattan’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-600	Closed	-$34K	–	1478
2015 Q3	$34K	Hold	600	–	–	﹤0.01%	1018
2015 Q2	$54K	Hold	600	–	–	﹤0.01%	950
2015 Q1	$57K	Hold	600	–	–	﹤0.01%	949
2014 Q4	$52K	Sell	600 -400	-40%	-$34.5K	﹤0.01%	972
2014 Q3	$91K	Hold	1,000	–	–	﹤0.01%	843
2014 Q2	$115K	Hold	1,000	–	–	﹤0.01%	782
2014 Q1	$121K	Hold	1,000	–	–	﹤0.01%	770
2013 Q4	$125K	Buy	1,000 +400	+67%	+$48K	﹤0.01%	758
2013 Q3	$65K	Buy	+600	New	+$58.5K	﹤0.01%	877

Other funds holding TRIB

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

AAM

ACK Asset Management Greenwich, Connecticut $801M AUM 60.42% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

LAM

Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return

First Manhattan's TRIB Position: Q4 2015 in Review

First Manhattan sold out of Trinity Biotech (TRIB) in Q4 2015, closing a stake of 600 shares — an estimated $34K sold.

First Manhattan first reported a position in TRIB in Q3 2013 and held it in 9 quarters. The position peaked at $125K in Q4 2013. 82 funds tracked by Wall St. Rank hold TRIB as of Q4 2015.

First Manhattan reported no remaining Trinity Biotech position as of Q4 2015 after selling out during the quarter.
First Manhattan sold 600 Trinity Biotech shares in Q4 2015, an estimated $34K.
First Manhattan first reported a position in Trinity Biotech in Q3 2013 and held it in 9 quarters.
First Manhattan's Trinity Biotech position peaked at $125K in Q4 2013.
82 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2015.

Based on First Manhattan's 13F filing for Q4 2015, filed 20 Jan 2016.